Kite claims a first for CAR-T Tecartus in adult leukaemia
The FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy […]
Oncology
GSK bails on $4.2bn partnership with Merck on cancer drug
GlaxoSmithKline has ended its collaboration with Germany’s Merck KGaA’s cancer treatment bintrafusp alfa, after a trio of failed clinical trials. Given the disappointments the decision […]
Blood Cancer UK: Hopes for our community’s future in the time of COVID
This thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness Month, Blood Cancer UK’s Kate Keightley explains […]
NICE clears NHS use of Roche’s Tecentriq in bladder cancer
NICE has recommended routine NHS access to Roche’s cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via […]
Bayer teams up with Huma to apply AI to lung cancer diagnosis
A research project between Bayer and digital health company Huma will use artificial intelligence to detect lung cancer in CT scans – and determine which […]
Keytruda’s liver cancer approval secured by new study
Merck & Co’s FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival […]
England’s cancer therapy backlog ‘could take more than a decade to shift’
A new report has suggested it could take until 2033 to clear the backlog of cancer treatment in England caused by the pandemic. The analysis […]
PROpel study backs Lynparza combo in first-line prostate cancer
AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the […]
Boehringer buys Abexxa, bolstering its immuno-oncology pipeline
Boehringer Ingelheim says it has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area in the space of a […]
FDA clears AI-powered prostate cancer detection software
Software that can help pathologists detect prostate cancer from slides of biopsies more effectively has been approved by the FDA. The software – called Paige […]
FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancer
Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line […]
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
There’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the tree in previously-untreated non-small cell lung cancer […]
ESMO21: Enhertu brings it’s A game to second-line breast cancer
AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche’s rival Kadcyla when they […]
ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs
Roche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective oestrogen receptor degraders (SERDs) hoping to provide […]
Keytruda backed by NICE for late-stage oesophageal cancer
MSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment. […]
ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC
Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting encouraging results when the drug is used […]
Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval
Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, but can now celebrate a vestry after […]
Assessing the Opportunities and Challenges in the Oncology Segment
Oncology is the study of cancer and encompasses the diagnosis and treatment of cancer. The treatment of cancer requires a multidisciplinary approach which includes medications, […]
Evaluating the Present and Future Oncology Market Outlook With Valued Research and Analysis
Oncology deals with the diagnosis and treatment of cancer. It is one of the most dynamic segments moving at a rapid pace in terms of […]
Rome Therapeutics raises $77m for junk DNA-targeting drugs
Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – […]
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab
Novartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier this year – as a second-line treatment […]
NHS England starts largest ever trial of Galleri cancer blood test
A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England […]
NHS fast tracks access to Amgen’s just-approved KRAS cancer drug
Amgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement to allow early access while its cost-effectiveness […]
Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment
What You Should Know: – Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and […]
Biotech Insight podcast: Overcoming planning challenges in oncology
The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular […]
AI ‘could help diagnose lung cancer a year earlier’
An artificial intelligence algorithm was able to detect signs of lung cancer on CT scans a year earlier than with traditional methods, according to a […]
NICE changes its mind on J&J’s Erleada in prostate cancer
NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use […]
Roche dives further into cancer cell therapy with Adaptimmune deal
Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for cancer, but it has made a big […]
Gamble by Takeda on unproven cancer mechanism draws a blank
Takeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – has failed to show a benefit in […]
Targeting COVID-19 and cancer with immunotherapy advancements
Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes […]
How pharma can help the post-COVID recovery of European cancer care
The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute […]
Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care
What You Should Know: – Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and […]
Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU
Incyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for […]
J&J lung cancer initiative will use Optellum’s ‘digital biomarker’ tech
Three years ago, Johnson & Johnson set up a wide-ranging initiative with Boston University to try to improve lung cancer survival rates through prevention and […]
Novartis’ bid to extend Kymriah into earlier use hits a roadblock
Novartis’ CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn’t added to its […]
Third strike for GSK/Merck as bintrafusp alfa flubs again
GlaxoSmithKline’s big gamble on Merck KGaA’s bintrafusp alfa has gone from bad to worse, after the drug failed yet another mid-stage trial. The latest disappointment […]
Pfizer vaults into CD47 arena, buying Trillium for $2.3 billion
Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a ‘don’t eat me’ signal that protects cancer […]
BMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapy
Bristol-Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer therapy, getting FDA approval for the drug for […]
FDA issues warning on robot-assisted breast cancer surgery
The FDA has issued a safety alert about the use of robot-assisted surgical (RAS) devices for use in mastectomy procedures, pointing out that their safety […]
GSK claims broader ’tissue-agnostic’ label for PD-1 drug Jemperli
The FDA has approved GlaxoSmithKline’s latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the patient population eligible for treatment with the […]
Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology
Shots: Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible […]
Merck’s Welireg becomes first drug for rare VHL tumours in US
Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as […]
NICE changes stance on Lilly’s breast cancer dug Verzenio
After rejecting Eli Lilly’s Verzenio for breast cancer therapy earlier this year, NICE has relented, recommending the drug for routine NHS use alongside hormonal therapy […]
FDA starts speedy review of Keytruda for adjuvant kidney cancer
Merck & Co is looking at a decision from the FDA in December on its application to market Keytruda as a post-surgery treatment for people […]
Collaborate to simplify cancer trials and accelerate post-pandemic recovery
How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic levels? Amanda Barrell reports from the ABPI […]
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn
Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi […]
Armed with ph3 trial, Roche preps filing for Polivy in first-line DLBCL
Roche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed diffuse large B-cell lymphoma (DLBCL) – an […]
Sanofi, Regeneron eye Libtayo challenge to Keytruda in first-line lung cancer
Sanofi and Regeneron’s latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for […]
Kite takes the ‘Appian way’ to off-the-shelf cell therapies for cancer
Gilead Sciences’ Kite Pharma has mapped out another route to the development of allogeneic or ‘off-the-shelf’ cell therapies for cancer, using technology developed by Appia […]
Bayer bolsters R&D platform with $2bn Vividion takeover
Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against […]
The Cancer Moonshot and beyond: What we need to succeed
U.S. government support can advance health breakthroughs and make a significant difference. I encourage you to support the creation of ARPA-H and to take specific […]
Failed trial nixes another FDA approval, this time for BMS’ Istodax
Bristol-Myers Squibb’s HDAC inhibitor Istodax has been on the US market for a decade as a treatment for peripheral T-cell lymphoma (PTCL), but will now […]
Roche gets fast FDA review for Tecentriq in adjuvant lung cancer
Roche is preparing for a December verdict form the FDA on adjuvant use of its PD-L1 inhibitor Tecentriq as an adjuvant treatment for some patients […]
Sanofi swoops on partner Translate, buying the mRNA firm for $3.2bn
Sanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together in 2018, and has now gone all […]
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal
Just three months after completing its $1.8 billion takeover of Agios’ oncology pipeline, Servier has reported positive results for lead drug Tibsovo that could expand […]
Cancer research faces uncertain post-COVID landscape
There’s a bright future ahead for cancer research in the UK, but only if the government is able to implement a clear plan for funding […]
BMS claims first EU okay for adjuvant oesophageal cancer immunotherapy
Bristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy market, and has just reinforced its position […]
Surprise pandemic lessons for pharma
Ask people in most western nations to think back to 2019 and consider what they would have said then about the potential impact of a […]
Lessons from the first generation of cell and gene oncology trials
Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for […]
AbbVie, Calico raise their age-related disease alliance funding to $3.5bn
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. […]
AbbVie, Calico raise their age-related disease alliance funding to $3.5bn
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. […]
After false start, Merck claims Keytruda approval in early breast cancer
Merck & Co’s Keytruda has just picked up its 30th approval from the FDA, and it is a good one – early-stage triple-negative breast cancer […]
Oncology R&D: the patient insights we’re still missing, and how to catch up
Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded. You are under pressure to bring […]
BMS pulls speedy Opdivo approval for liver cancer in US
Bristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for hepatocellular carcinoma, a common form of liver […]
Digital tools key to immuno-oncology’s future: report
If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the […]
Pfizer puts up $1bn to buy into Arvinas breast cancer programme
Pfizer has pledged a whopping $11 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells’ […]
NICE changes its mind on rare bile duct cancer drug from Incyte
Incyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, after NICE concluded it provided value for […]
Oncology and a year of COVID: lessons for the future
COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting […]
Arcus’ CMO Grossman jumps ship to join Gilead’s cancer push
Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief medical officer Bill Grossman to a new […]
BioNTech grows in cell therapies, buying Kite’s TCR platform
BioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 vaccine, agreeing a deal to buy Kite […]
How hybrid virtual engagement is accelerating oncology communication
COVID has revolutionised the way pharma engages with healthcare stakeholders – but to be truly successful, digital engagement needs to move away from an overreliance […]
AstraZeneca bags Imfinzi okay in big Chinese lung cancer market
China has approved AstraZeneca’s PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the disease that accounts for around 15% of […]
Enabling healthcare’s digital future
Debiopharm Innovation Fund’s Tanja Dowe on investing in digital health start-ups and supporting them on their rollercoaster rides to improve patient outcomes The weight of […]
NICE second Zytiga rejection ‘shows need for flexible pricing models’
NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a treatment for men with newly diagnosed advanced […]
What HCPs think about health equity in cancer care
After more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually evident disparities that many are facing in […]
Digital health developments: a new investment era for start-ups
Healthware Labs’ Kristin Milburn explores how digital health start-ups can harness the huge potential for the sector in a post-COVID world and the paths they […]
Why pharma shouldn’t forget about sites in a post-COVID world
The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to […]
GSK cancer head Hoos exits, takes top role at biotech Scorpion
GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion […]
Imugene HER2 vaccine hits target in stomach cancer trial
A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in […]
When biotech meets reality TV – Starton Therapeutics faces the Unicorn Hunters
Starton Therapeutics is bypassing the traditional venture capital route to raise money for its transdermal delivery technology that delivers medicine through the skin. pharmaphorum hears […]
Health Innovators: Eliot Forster, F-Star
In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, NASDAQ-listed biopharmaceutical company focused on transforming the […]
Merck pulls Keytruda’s FDA nod for third-line stomach cancer
Merck & Co will voluntarily withdraw a US marketing approval for cancer immunotherapy blockbuster Keytruda in gastric cancer, after studies intended to confirm its efficacy […]
BMS pays $650m upfront for Eisai’s first ADC candidate for cancer
Japan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing deal from Bristol-Myers Squibb that could top […]
Gilead combs Shoreline for NK cell therapies in $2.3bn alliance
Gilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership […]
Blueprint’s latest approval for Ayvakit sets up clash with Novartis
Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), a group of rare blood cancers currently […]
Ambrx tries another IPO as it chases down HER2 rivals
California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in […]
Exscientia buys Allcyte to add patient sample testing to its AI platform
UK-based artificial intelligence pioneer Exscientia has made a play to stay at the forefront of the field, acquiring Austrian rival Allcyte with the help of […]
GSK joins ant-TIGIT push with $625m upfront iTeos deal
GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with […]
Daiichi Sankyo claims first okay for oncolytic virus in Japan
Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer […]
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line […]
Country focus: China & APAC’s growing medical needs bring opportunities and challenges
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating […]
Scotland backs rare blood cancer drug Poteligeo rejected by NICE
A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Poteligeo for two rare blood cancers, a […]
J&J backs out of $1.6bn blood cancer antibody alliance with Argenx
Belgian biotech Argenx has lost its development partner for acute myeloid leukaemia antibody cusatuzumab, after Johnson & Johnson backed away from the alliance after two […]
ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data
AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in chronic lymphocytic leukaemia (CLL) that it says […]
ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data
Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences’ Kite subsidiary is now looming […]
Prostate Cancer Drug Development Summit
The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of […]
ASCO21: Lynparza aces adjuvant breast cancer therapy trial
AstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer after a phase 3 trial showed it […]
Bayer props up sagging radionuclide business with Noria acquisition
Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its […]
ASCO21: Novartis’ prostate cancer radiotherapy extends survival
Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment […]
Changing focus to cachexia may be key to improved cancer outcomes
Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr. Daniel L Marks discusses […]
Genmab takes aims at immuno-oncology antibody conjugates with Bolt Bio
Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be […]
PAVmed Launches Veris Health With Acquisition of Oncodisc –M&A
What You Should Know: – PAVmed announced today their launch of digital health company, Veris Health, along with Veris’ acquisition of Oncodisc. – Oncodisc was created by […]
MorphoSys offers $1.7bn for Constellation, but investors see stars
Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to buy its US rival Constellation Pharma and […]
Amgen nabs speedy approval for first-ever KRAS drug sotorasib
After decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that inhibits KRAS – a cancer target that […]
FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-cel
Johnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), narrowing the lead for Bristol-Myers Squibb and […]
New Cell & Gene Therapy Collective seeks to boost UK adoption
The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – […]
Straight after its first cancer bispecific OK, J&J highlights two more at ASCO
With the ink barely dry on the FDA’s approval of Johnson & Johnson’s Rybrevant, its first bispecific antibody for cancer, the drugmaker is already showcasing […]
Janssen claims FDA okay for would-be Tagrisso rival Rybrevant
Johnson & Johnson’s Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell […]
ChristianaCare added a primary care practice to its cancer center. Here’s why.
When ChristianaCare’s Graham Cancer Center saw that a significant number of its patients did not have a primary care provider, they decided to take action. […]
Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy
In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the CAR-T cancer cell therapies they had just […]
Vinehealth earns CE marks for cancer management apps
UK digital health firm Vinehealth has won a CE mark for a mobile app that helps cancer patients manage their medications and care, as well […]
LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies
LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year’s ASCO conference after trial results showed […]
Numab raises $110m to develop cancer bispecific antibodies
Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, […]
BMS Extends its 2019 Collaboration with Exscientia for AI Driven Drug Discovery
Shots: Exscientia to receive ~$50M as up front, ~$125M as milestones and additional clinical, regulatory, and commercial milestones of over $1.2B along with royalties on […]
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option
The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such […]
BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drug
Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs […]
AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan
AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient […]
Patients in England get fast access to AZ’s Tagrisso in early lung cancer
The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast […]
NICE says no to Merck Serono’s Bavencio in bladder cancer
Merck Serono’s Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE […]
Roche’s Tecentriq gets fourth European lung cancer indication
Roche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of certain patients with metastatic non-small cell lung […]
Janssen files its first CAR-T therapy cilta-cel in Europe
Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers […]
Keytruda should lose stomach cancer indication, says ODAC
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co’s Keytruda of its accelerated approval in gastric and gastroesophageal junction (GEJ) […]
ODAC votes to keep bladder cancer labels for Keytruda, Tecentriq
Merck & Co’s Keytruda and Roche’s Tecentriq should stay on the market as first-line treatments for bladder cancer, at least until new clinical data becomes […]
Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts say
Roche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to the FDA have said as part of […]
FDA looks at pulling speedy approvals for three cancer drugs
FDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see if they should stay on the market. […]
Proton Therapy – Ultimate Guide for Patients
Proton therapy is expected to be the next big thing in future of medical science. The advanced mode of treatment deserves all the hype it […]
Enhertu cleared for NHS use via Cancer Drugs Fund
NICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the drug has been commissioned in any European […]
J&J decides against Erleada+Zytiga combination prostate cancer filing
Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, after a phase 3 trial showed it […]
Astellas, Seagen seek speedy reviews of Padcev in bladder cancer
The next milestone in Seagen and Astellas’ bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster will come in August, when the FDA […]
Non-Small Cell Lung Cancer Drug Development Summit
The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. This is a strategic conference designed […]
Komodo Health Launches Next-Gen AI to Accelerate Innovation and Close Gaps in Care
What You Should Know: – Today, Komodo Health is capping off a month-long flurry of activity by announcing the launch of its Prism and Sentinel solutions — opening up […]
Boehringer and MD Anderson extend KRAS cancer collaboration
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations. […]
Gilead’s Trodelvy approved in metastatic urothelial cancer
Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Trodelvy (sacituzumab govitecan) has been approved for […]
AZ aims at Pfizer, GSK with potential new PARP cancer drug
AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer. The drug […]
PHINs: Addressing the Fundamental Flaws that Have Broken Healthcare
Brad Bostic, CEO, hc1 The fundamental problem with healthcare can be summed up in one sentence: We expect healthcare services that cater to our individual […]
STING & TLR Targeting Therapies Summit
This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as […]
Exscientia starts trials of first AI-derived cancer immunotherapy
Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has […]
The next generation of immunotherapy? Innate Pharma targets NK cells
Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer. Catherine Longworth spoke to CEO […]
Merck’s Keytruda demonstrates adjuvant use in kidney cancer
Merck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for the potential adjuvant treatment of patients with […]
Cancer Research UK spinout Achilles raises $175.5m in IPO
UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised […]
Gilead scores US approval for breast cancer drug that wowed ESMO
Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA […]
Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching
What You Should Know: – Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, […]
Novartis expands in radio-oncology again with $1.3bn Artios alliance
In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to […]
Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases
That is the title of a paper I just published at Value in Health with Suepattra G. May, Lauren M. Zhao, Katalin Bognar, Yong Yuan, […]
9th PREDiCT: Tumor Models Cell Therapy Summit
With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. There is a crucial need to progress […]
3rd Cell Engager Summit
With that in mind, the 3rd Cell Engager Summit (June 30 – July 1) is the only industry-led meeting focused on developing multi-specific cell engaging therapies in solid tumor indications, […]
Sanofi’s Sarclisa gains new US multiple myeloma indication
The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. […]
Country focus: Hungary carves out a niche in digital pharma
AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO […]
Novartis builds radio-oncology pipeline with iTheranostics deal
Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where […]
TG Therapeutics completes FDA filing for Roche challenger in CLL
TG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab with the oral drug Ukoniq (umbralisib) as […]
FDA approves BMS’ multiple myeloma CAR-T Abecma
The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease. Abecma’s review was delayed after […]
To Advance Health Equity, Put Real-World Cancer Data to Work
Dr. Miller, Medical Director of CancerLinQ LLC Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — […]
